All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00071569" target="_blank" >RIV/00216224:14110/13:00071569 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.4172/2155-9864.1000167" target="_blank" >http://dx.doi.org/10.4172/2155-9864.1000167</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.4172/2155-9864.1000167" target="_blank" >10.4172/2155-9864.1000167</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia

  • Original language description

    Purpose: The objective of this study was to evaluate the quality of life (QL) as well as the frequency and severity of depression in patients with chronic phase chronic myeloid leukemia (CP-CML) in relation to the duration of Imatinib treatment. Methods:A detailed analysis of 56 adult patients with CP CML divided into groups according to the length of Imatinib treatment was performed as follows: Group A (n=28)- patients treated for 15 months (median); and Group B (n=28)-patients treated for 50 months (median). All used questionnaires EORTC QLQ-C30 (version 2), SF 36 and BDI were localized and validated. Results: The results from the QL questionnaires found a trend in the improvement in the QL of patients treated with Imatinib for 50 months (median) compared to patients treated for 15 months (median) only. However, a statistically significant improvement in the QL of patients with longer Imatinib treatment was found only in patients without co-existing invalidity and/or rheumatic disea

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    Z - Vyzkumny zamer (s odkazem do CEZ)

Others

  • Publication year

    2013

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of Blood Disorders & Transfusion

  • ISSN

    2155-9864

  • e-ISSN

  • Volume of the periodical

    4

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    5

  • Pages from-to

    1000167

  • UT code for WoS article

  • EID of the result in the Scopus database